Recently Featured

CARsgen makes history as China approves world’s first CAR-T therapy for solid tumors

June 28, 2026
CARsgen Therapeutics has achieved a significant milestone with the approval of the world’s first CAR-T therapy targeting solid tumors, specifically for Claudin18.2. This groundbreaking therapy marks a pivotal moment in the oncology landscape, as it is the first CAR-T cell therapy to receive global approval for treating solid tumors, which have historically posed challenges for…

Bionyra Secures $165M for Next-Generation Immune Drugs

June 28, 2026
Bionyra, a biotech company co-founded by Sofinnova Partners and a former head of immunology R&D at Sanofi, has successfully raised $165 million to advance its development of next-generation biologics targeting common immune conditions. This significant funding round underscores the growing investor interest in innovative therapies that address unmet medical needs in the immunology space. The…

Moderna’s mRNA flu vaccine passes FDA AdCom, review underway

June 27, 2026
Moderna’s mRNA flu vaccine has received unanimous support from the FDA Advisory Committee, which concluded that the benefits of the vaccine outweigh its risks for specific age groups. This endorsement is a significant milestone in the ongoing evaluation of mRNA technology beyond COVID-19 applications, indicating a shift towards broader utilization of innovative vaccine platforms in…

HLTH Europe 2026: Enriching the Patient Journey with Health Technologies

June 27, 2026
At HLTH Europe 2026, industry experts emphasized the critical role of patient adherence-focused health technologies in enhancing the overall patient journey. These technologies are increasingly recognized for their potential to improve health outcomes through better engagement and support for patients navigating their treatment pathways. The discussions highlighted that for these health technologies to be effective,…

Ongoing Cases